FORA Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

FORA Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.48M	Buy	4,471 +1,005	+29%	+$342K	0.11%	193
2025 Q4	$1.38M	Buy	3,466 +747	+27%	+$331K	0.17%	160
2025 Q3	$1.24M	Buy	+2,719	New	+$1.11M	0.22%	124
2025 Q2	–	Sell	-8,624	Closed	-$2.33M	–	493
2025 Q1	$2.33M	Sell	8,624 -4,074	-32%	-$1.05M	0.24%	137
2024 Q4	$2.99M	Buy	+12,698	New	+$3.34M	0.34%	94
2024 Q3	–	Sell	-7,173	Closed	-$1.74M	–	429
2024 Q2	$1.74M	Buy	+7,173	New	+$1.13M	0.21%	154
2024 Q1	–	Sell	-1,705	Closed	-$326K	–	398
2023 Q4	$326K	Buy	+1,705	New	+$290K	0.03%	382
2022 Q4	–	Sell	-8,774	Closed	-$1.76M	–	452
2022 Q3	$1.76M	Buy	+8,774	New	+$1.67M	0.34%	87
2021 Q4	–	Sell	-2,229	Closed	-$421K	–	301
2021 Q3	$421K	Sell	2,229 -435	-16%	-$81.6K	0.11%	230
2021 Q2	$452K	Buy	+2,664	New	+$390K	0.08%	282
2020 Q3	–	Sell	-7,026	Closed	-$1.04M	–	639
2020 Q2	$1.04M	Buy	+7,026	New	+$947K	0.36%	62
2020 Q1	–	Sell	-10,529	Closed	-$1.21M	–	1015
2019 Q4	$1.21M	Buy	+10,529	New	+$1.05M	0.12%	221

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FORA Capital's ALNY Position: Q1 2026 in Review

FORA Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 29% in Q1 2026, buying an estimated $342K and bringing the position to 4,471 shares worth $1.48M. The position accounts for 0.11% of the portfolio, ranked #193.

FORA Capital first reported a position in ALNY in Q4 2019 and has held it in 12 quarters since. The position peaked at $2.99M in Q4 2024. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

FORA Capital held 4,471 shares of Alnylam Pharmaceuticals worth $1.48M as of Q1 2026.
FORA Capital bought 1,005 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $342K.
Alnylam Pharmaceuticals made up 0.11% of FORA Capital's portfolio in Q1 2026, its #193 holding.
FORA Capital first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 12 quarters since.
FORA Capital's Alnylam Pharmaceuticals position peaked at $2.99M in Q4 2024.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.